Morgan Stanley set a GBX 5,000 ($65.76) target price on AstraZeneca plc (LON:AZN) in a research report report published on Friday. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.
Other research analysts have also issued reports about the stock. Liberum Capital reissued a buy rating and issued a GBX 5,500 ($72.34) target price on shares of AstraZeneca plc in a report on Thursday, July 27th. Kepler Capital Markets reissued a buy rating and issued a GBX 5,500 ($72.34) target price on shares of AstraZeneca plc in a report on Thursday, July 13th. Citigroup Inc. reaffirmed a buy rating and set a GBX 6,000 ($78.92) price objective on shares of AstraZeneca plc in a research note on Thursday, July 13th. Deutsche Bank AG reaffirmed a buy rating and set a GBX 5,700 ($74.97) price objective on shares of AstraZeneca plc in a research note on Friday, July 28th. Finally, Berenberg Bank set a GBX 5,500 ($72.34) price objective on shares of AstraZeneca plc and gave the stock a buy rating in a research note on Friday, July 28th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. AstraZeneca plc currently has an average rating of Hold and an average target price of GBX 5,247.18 ($69.01).
AstraZeneca plc (LON AZN) opened at GBX 4,932.50 ($64.88) on Friday. AstraZeneca plc has a fifty-two week low of GBX 3,996 ($52.56) and a fifty-two week high of GBX 5,520 ($72.60).
COPYRIGHT VIOLATION NOTICE: This report was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.thestockobserver.com/2017/11/14/morgan-stanley-reiterates-gbx-5000-price-target-for-astrazeneca-plc-azn.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.